Acelrx Pharmaceuticals Inc прибыль на акцию
Что обозначает прибыль на акцию в Acelrx Pharmaceuticals Inc?
прибыль на акцию Acelrx Pharmaceuticals Inc является N/A
Какое определение для прибыль на акцию?
Прибыль на акцию (EPS) - это часть прибыли компании, распределяемая на каждую находящуюся в обращении обыкновенную акцию. Она скорректирована с учетом ослабления и рассчитана в течение двенадцати месяцев.
Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. Preferred stock rights have precedence over common stock. Therefore, dividends on preferred shares are subtracted before calculating the EPS. When preferred shares are cumulative, annual dividends are deducted whether or not they have been declared. Dividends in arrears are not relevant when calculating EPS. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.
Что делает Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v